Ebola: Symptoms, treatment, and causes
Pathogenesis Of Bacterial Meningitis: From Bacteraemia To Neuronal Injury
Fauci, A. S. Infectious diseases: considerations for the 21st century. IDSA Lecture Clin. Infect. Dis. 32, 675–685 (2001).
Dawson, K. G., Emerson, J. C. & Burns J. L. Fifteen years of experience with bacterial meningitis. Pediatr. Infec. Dis. J. 18, 816–822 (1999).
Grimwood, K., Anderson, P., Anderson V., Tan, L. & Nolan, T. Twelve-year outcomes following bacterial meningitis: further evidence for persisting effects. Arch. Dis. Child. 83, 111–116 (2000).
Pfister, H. -W., Fontana, A., Tauber, M. G. Tomasz, A. & Scheld, W. M. Mechanisms of brain injury in bacterial meningitis: workshop summary. Clin. Infect. Dis. 19, 463–479 (1994).
Van Furth, A. M., Roord, J. J. & Van Furth, R. Roles of proinflammatory and anti-inflammatory cytokines in pathology of bacterial meningitis and effect of adjunctive therapy. Infect. Immun. 64, 4883–4890 (1996).
Tauber, M. G. & Moser, B. Cytokines and chemokines in meningeal inflammation: biology and clinical implications. Clin. Infect. Dis. 28, 1–12 (1999).
Scheld, W. M., Koedel, U., Nathan, B. & Pfister, H. -W. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J. Infect. Dis. Suppl. 186, S225–233 (2002). A comprehensive review on neuronal injury in bacterial meningitis.
Marra, A. & Brigham, M. D. Streptococcus pneumoniae causes experimental meningitis following intranasal and otitis media infections via a nonhematogenous route. Infect. Immun. 69, 7318–7325 (2001).
Braun, J. S. Et al. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nature Med. 5, 298–302 (1999).
Nau, R., Soto, A. & Bruck, W. Apoptosis of neurons in the dentate gyrus in humans suffering from bacterial meningitis. J. Neuropath. Exp. Neurol. 58, 265–274 (1999).
Rubin, L. L. & Staddon, J. M. The cell biology of the blood–brain barrier. Annu. Rev. Neurosci. 22, 11–28 (1999).
Kim, K. S. Escherichia coli translocation of the blood–brain barrier. Infect. Immun. 69, 5217–5222 (2001). A review on bacterial translocation of the blood–brain barrier.
Kim, K. S. Et al. The K1 capsule is the critical determinant in the development of Escherichia coli meningitis in the rat. J. Clin. Invest. 90, 897–905 (1992).
Robbins, R. B. Et al. Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N. Engl. J. Med. 290, 1216–1220 (1974).
Gross, R. J., Ward, L. R., Threlfall, E. J., Cheasty, T. & Rowe, B. Drug resistance among Escherichia coli strains isolated from cerebrospinal fluid. J. Hyg. 90, 195–198 (1982).
Korhonen, T. K. Et al. Serotypes hemolysin production and receptor recognition of Escherichia coli strains associated with neonatal sepsis and meningitis. Infect. Immun. 488, 486–491 (1985).
Sarff, L. D. Et al. Epidemiology of Escherichia coli in healthy and diseased newborns. Lancet 1, 1099–1104 (1975).
Kim, K. S., Wass, C. A. & Cross, A. S. Blood–brain barrier permeability during the development of experimental bacterial meningitis in the rat. Exp. Neurol. 45, 253–257 (1997).
Stins, M. F., Badger, J. L. & Kim, K. S. Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells. Microb. Pathog. 30, 19–28 (2001).
Dietzman, D. E., Fischer, G. W. & Schoenknecht, F. D. Neonatal Escherichia coli septicemia — bacterial counts in blood. J. Pediatr. 85, 128–130 (1974).
Bell, L. M., Alpert, G., Campos, J. M. & Plotkin, S. A. Routine quantitative blood cultures in children with Haemophilus influenzae or Streptococcus pneumoniae bacteremia. Pediatrics 76, 901–904 (1985).
Ferrieri, P., Burke, B. & Nelson, J. Production of bacteremia and meningitis in infant rats with group B streptococcal serotypes. Infect. Immun. 27, 1023–1032 (1980).
Moxon, E. R. & Ostrow, P. T. Haemophilus influenzae meningitis in infant rats: role of bacteremia in pathogenesis of age-dependent inflammatory responses in cerebrospinal fluid. J. Infect. Dis. 135, 303–307 (1977).
Sullivan, T. D., LaScolea, L. J. & Neter, E. Relationship between the magnitude of bacteremia in children and the clinical disease. Pediatrics 69, 699–702 (1982).
Petersdorf, R. G., Swarner, D. R. & Garcia, M. Studies on the pathogenesis of meningitis II. Development of meningitis during pneumococcal bacteremia. J. Clin. Invest. 41, 320–327 (1962).
Cross, A. S., Kim, K. S., Wright, D. C., Sadoff, J. C. & Gemski, P. Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli. J. Infect. Dis. 154, 497–503 (1986).
Khan, N. A. Et al. Gp96 is a receptor for OmpA in human brain microvascular endothelial cells. Abstr. 102ndGen. Meet. Am. Soc. Microbiol. B216 (2002).
Khan, N. A., Elliott, S. J. & Kim, K. S. Role of FimH in Escherichia coli interactions with human brain microvascular endothelial cells. Abstr. 102ndGen. Meet. Am. Soc. Microbiol. B59 (2002).
Prasadarao, N. V., Wass, C. A. & Kim, K. S. Endothelial cell GlcNAcβ-4GlcNAc epitopes for outer membrane protein A enhance traversal of Escherichia coli across the blood–brain barrier. Infect. Immun. 64, 154–160 (1996).
Parkkinen, J., Korhonen, T. K., Pere, A., Hacker, J. & Soiinilla, S. Binding sites of the rat brain for Escherichia coli S-fimbriae associated with neonatal meningitis. J. Clin. Invest. 81, 860–865 (1988).
Stins, M. F. Et al. Binding characteristics of S-fimbriated Escherichia coli to isolated brain microvascular endothelial cells. Am. J. Pathol. 145, 1228–1236 (1994).
Prasadarao, N. V., Wass, C. A., Hacker, J., Jann, K. & Kim, K. S. Adhesion of S-fimbriated Escherichia coli to brain glycolipids mediated by sfaA gene-encoded protein of S-fimbriae. J. Biol. Chem. 268, 10356–10363 (1993).
Huang, S. H. Et al. Escherichia coli invasion of brain microvascular endothelia cell in vitro and in vivo: molecular cloning and characterization of invasion gene ibe10. Infect. Immun. 63, 4470–4475 (1995).
Huang, S. H. Et al. Identification and characterization of an Escherichia coli invasion gene locus, ibeB, required for penetration of brain microvascular endothelia cells. Infect. Immun. 67, 2103–2109 (1999).
Wang, Y., Huang, S. H., Wass, C. & Kim, K. S. The gene locus yijP contributes to Escherichia coli K1 invasion of brain microvascular endothelial cells. Infect. Immun. 67, 4751–4756 (1999).
Badger, J., Wass, C., Weissman, S. & Kim, K. S. Application of signature-tagged mutagenesis for the identification of Escherichia coli K1 genes that contribute to invasion of the blood–brain barrier. Infect. Immun. 68, 5056–5061 (2000).
Khan, N. A. Et al. Cytotoxic necrotizing factor-1 contributes to Escherichia coli K1 invasion of the central nervous system. J. Biol. Chem. 277, 15607–15612 (2002). The first study to show the contributions of CNF1 and RhoA activation to E. Coli K1 invasion of the CNS.
Prasadarao, N. V. Et al. Outer membrane protein A of Escherichia coli contributes to invasion of brain microvascular endothelial cells. Infect. Immun. 64, 146–153 (1996).
Prasadarao, N. V., Wass, C. A., Huang, S. -H. & Kim, K. S. Identification and characterization of a novel Ibe 10 binding protein that contributes to Escherichia coli invasion of brain microvascular endothelial cells. Infect. Immun. 67, 1131–1138 (1999).
Chung, J. W. Et al. 37kDa lamina receptor precursor modulates cytotoxic necrotizing factor 1-mediated RhoA activation and bacterial uptake. J. Biol. Chem. (in the press). This paper shows the identification of 37LRP as the receptor for CNF1.
Prasadarao, N. A., Wass, C. A., Stins, M. F., Shimada, H. & Kim, K. S. Outer membrane protein A-promoted actin condensation of brain microvascular endothelial cells is required for Escherichia coli invasion. Infect. Immun. 67, 5775–5783 (1999).
Reddy, M. A., Wass, C. A., Kim, K. S., Schlaepfer, D. D. & Prasadarao, N. V. Involvement of focal adhesion kinases in Escherichia coli invasion of human microvascular endothelial cells. Infect. Immun. 68, 6419–6422 (2000).
Reddy, M. A., Prasadarao, N. V., Wass, C. A. & Kim, K. S. Phosphatidylinositol 3-kinase activation and interaction with focal adhesion kinase in Escherichia coli K1 invasion of human brain microvascular endothelial cells. J. Biol. Chem. 275, 36769–36774 (2000). This paper shows that activations of FAK and PI3K are required for E. Coli K1 invasion of human brain microvascular endothelial cells.
Das, A. Et al. Differential role of cytosolic phospholipase A2 in the invasion of brain microvascular endothelial cells by Escherichia coli and Listeria monocytogenes. J. Infect. Dis. 184, 732–737 (2001).
Greiffenberg, L. Et al. Interaction of Listeria monocytogenes with human brain microvascular endothelial cells: InlB-dependent invasion, long-term intracellular growth, and spread from macrophages to endothelial cells. Infect. Immun. 66, 5260–5267 (1998).
Nizet, V. Et al. Invasion of brain microvascular endothelial cells by group B streptococci. Infect. Immun. 65, 5074–5081 (1997).
Hoffman, J. A., Wass, C., Stins, M. F. & Kim, K. S. The capsule supports survival but not traversal of Escherichia coli K1 across the blood–brain barrier. Infect. Immun. 67, 3566–3570 (1999).
Kim, K. J., Elliott, S. A., DiCello, F., Stins, M. F. & Kim K. S. The K1 capsule modulates trafficking of Escherichia coli-containing vacuoles and enhances intracellular bacterial survival in human brain microvascular endothelial cells. Cell. Microbiol. (in the press). This paper shows a new phenotype associated with the K1 capsule in E. Coli movement in human brain microvascular endothelial cells.
Saukkonen, K. Et al. The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis. J. Exp. Med. 171, 439–448 (1990).
Mustafa, M. M. Et al. Tumor necrosis factor in mediating experimental Haemophilus influenzae type B meningitis. J. Clin. Invest. 84, 1253–1259 (1989).
Tuomanen, E., Saukkonen, K., Sande, S., Cioffe, C. & Wright, S. D. Reduction of inflammation, tissue damage and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes. J. Exp. Med. 170, 959–968 (1989).
Tan, T. Q., Smith, C. W., Hawkins, E. P., Mason, E. O., Jr & Kaplan, S. L. Hematogenous bacterial meningitis in an intercellular adhesion molecule-1-deficient infant mouse model. J. Infect. Dis. 171, 342–349 (1995).
Munoz, F. M., Hawkins, E. P., Bullard, D. C., Beaudet, A. L. & Kaplan, S. L. Host defense against systemic infection with streptococcus pneumoniae is impaired in E-, P-, and E-/P- selectin-deficient mice. J. Clin. Invest. 100, 2099–2106 (1997).
Tauber, M. G., Borschberg, U. & Sande, M. A. Influence of granulocytes on brain edema, intracranial pressure and cerebrospinal fluid concentrations of lactate and protein in experimental meningitis. J. Infect. Dis. 157, 456–464 (1988).
Lesse, A. J., Moxon, E. R., Zwahlen, A. & Scheld, W. M. Role of cerebrospinal fluid pleocytosis and Haemophilus influenzae type b capsule on blood–brain barrier permeability during experimental meningitis in the rat. J. Clin. Invest. 82, 102–109 (1988).
Fishbein, D. B., Palmer, D. L., Porter, K. M. & Reed, W. P. Bacterial meningitis in the absence of CSF pleocytosis. Arch. Intern. Med. 141, 1369–1372 (1981).
Lukes, S. A., Posner, J. B., Nielsen, S. & Armstrong, D. Bacterial infections of the CNS in neutropenic patients. Neurology 34, 269–275 (1984).
Bergstrom, T., Larson, H., Lincoln, K. & Winberg, J. Studies of urinary tract infection in infancy and childhood. J. Pediatr. 80, 858–866 (1972).
Syrogiannopoulos, G. A. Et al. Sterile cerebrospinal fluid pleocytosis in young infants with urinary tract infection. Pediatr. Infect. Dis. J. 20, 927–930 (2001).
Laflamme, N. & Rivest, S. Toll-like receptor 4: the missing link of the central innate immune response triggered by circulating gram-negative bacterial cell wall components. FASEB J. 15, 155–63 (2001).
Kastenbauer, S., Koedel, U., Becker, B. F. & Pfister, H. -W. Pneumococcal meningitis in the rat: evaluation of peroxynitrite scavengers for adjunctive therapy. Eur. J. Pharmacol. 449, 177–181 (2002).
Koedel, U., Winkler, F., Angele, B., Fontana, A. & Pfister, H. -W. Meningitis-associated central nervous system complications are mediated by the activation of poly(ADP-ribose) polymerase. J. Cereb. Blood Flow Metab. 22, 39–49 (2002).
Winkler, F., Koedel, U., Kastenbauer, S. & Pfister, H. -W. Differential expression of nitric oxide syntheses in bacterial meningitis: role of the inducible isoform for blood–brain barrier breakdown. J. Infect. Dis. 183, 1749–1759 (2001).
Koedel, U. Et al. Lack of endothelial nitric oxide synthase aggravates murine pneumococcal meningitis. J. Neuropathol. Exp. Neurol. 11, 1041–50 (2001).
Paul, R. Et al. Matrix metalloproteinases contribute to the blood–brain barrier disruption during bacterial meningitis. Ann. Neurol. 44, 592–600 (1998).
Leppert, D., Leib, S. L., Grygar, C. & Miller, K. M. Matrix metalloproteinases (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood–brain barrier damage and neurological sequelae. Clin. Infect. Dis. 31, 80–84 (2000).
Kieseier, B. C. Et al. Differential expression of matrix metalloproteinases in bacterial meningitis. Brain 122, 1579–1587 (1999).
Koedel, U., Bayerlein, I., Paul, R., Sporer, B. & Pfister, H. -W. Pharmacologic interference with NF-κB activation attenuates central nervous system complications in experimental pneumococcal meningitis. J. Infect. Dis. 182, 1437–1445 (2000).
Koedel, U. Et al. Role of caspase-1 in experimental pneumococcal meningitis: evidence from pharmacologic caspase inhibition and caspase-1-deficient mice. Ann. Neurol. 51, 319–329 (2001).
Lebel, M. H., et al. Dexamethasone therapy for bacterial meningitis. N. Engl. J. Med. 319, 964–971 (1988). This paper shows the beneficial effect of dexamethosone therapy in reducing hearing deficits in children with H. Influenzae type b meningitis.
Ward, E. R. Et al. Dexamethasone therapy for children with bacterial meningitis. Pediatr. 95, 21–28 (1995).
Zysk, G. Et al. Anti-inflammatory treatment influences neuronal apoptotic cell death in the dentate gyrus in experimental pneumococcal meningitis. J. Neuropathol. Exp. Neurol. 55, 722–728 (1996).
De Gans, J. & van de Beek, D. Dexamethasone in adults with bacterial meningitis. N. Engl. J. Med. 347, 1549–1615 (2002).
Leib, S. L., Kim, Y. S., Chow, L. L., Sheldon, R. A. & Tauber, M. G. Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B streptococci. J. Clin. Invest. 98, 2632–2639 (1996). Highlights the role of reactive oxygen species in neuronal injury associated with experimental group B streptococcal meningitis.
Auer, M., Pfister, L. A., Leppert, D., Tauber, M. G. & Leib, S. L. Effects of clinically used antioxidants in experimental pneumococcal meningitis. J. Infect. Dis. 182, 347–350 (2000).
Koedel, U. & Pfister, H. W. Protective effect of the antioxidant N-acetyl-L-cysteine in pneumococcal meningitis in the rat. Neurosci. Lett. 225, 33–36 (1997).
Loeffler, J. M., Ringer, R., Hablutzel, M., Tauber, M. G. & Leib, S. L. The free radical scavenger α-phenyl-tert-butyl nitrone aggravates hippocampal apoptosis and learning deficits in experimental pneumococcal meningitis. J. Infect. Dis. 183, 247–252 (2001).
Koedel, U. Et al. Experimental pneumococcal meningitis: cerebrovascular alterations, brain edema, and meningeal inflammation linked to the production of nitric oxide. Ann. Neurol. 37, 313–323 (1995).
Leib, S. L., Kim, Y. S., Black, S. M., Tureen, J. H. & Tauber, M. G. Inducible nitric oxide synthase and the effect of aminoguanidine in experimental neonatal meningitis. J. Infect. Dis. 177, 692–700 (1998).
Radi, R., Beckman, J. S., Bush, K. M. & Freeman, B. A. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys. 288, 481–487 (1991).
Ischiropoulos, H. Et al. Peroxynitrite- mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 298, 431–437 (1992).
Bolanos, J. P., Heales, S. J., Land, J. M. & Clark, J. B. Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurons and astrocytes in primary culture. J. Neurochem. 64, 1965–1972 (1995).
Szabo, C. Cell Death: The Role of PARP (CRC Press, Boca Raton, Florida, 2000).
McCracken, G. H. Jr, Sarff, L. D., Glode, M. P. & Mize, S. G. Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet 2, 246–250 (1974).
Mertsola, J., et al. Endotoxin concentrations in cerebrospinal fluid correlate with clinical severity and neurologic outcome of Haemophilus influenzae type B meningitis. Am. J. Dis. Child. 145, 1099–1103 (1991).
Schneider, O., Michel, U., Zysk, G., Dubuis, O. & Nau, R. Clinical outcome in pneumococcal meningitis correlates with CSF lipoteichoic acid concentrations. Neurology 53, 1584–1587 (1999).
McCracken, G. H. Jr, Mustafa, M. M., Ramilo, O., Olsen, K. D. & Risser, R. C. Cerebrospinal fluid interleukin 1β and tumor necrosis factor concentrations and outcome from neonatal Gram-negative enteric bacillary meningitis. Pediatr. Infect. Dis. J. 8, 155–159 (1989).
Mustafa, M. M. Et al. Correlation of interleukin-1β and cachectin concentrations in cerebrospinal fluid and outcome from bacterial meningitis. J. Pediatr. 115, 208–213 (1989).
Ichiyama, T., Hayashi, T., Nishikawa, M. & Furukawa, S. Levels of transforming growth factor β1, tumor necrosis factor α, and interleukin 6 in cerebrospinal fluid: association with clinical outcome for children with bacterial meningitis. Clin. Infect. Dis. 25, 328–329 (1997).
Leib, S. L. Et al. Inhibition of matrix metalloproteinases and tumor necrosis factor-α converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 124, 734–1742 (2001). This study highlights the roles of MMPs and TNFα converting enzyme in neuronal injury associated with experimental pneumococcal meningitis.
Leib, S. L., Leppert, D., Clements, J. & Tauber, M. G. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect. Immun. 68, 615–620 (2000).
Bogdan, I., Leib, S. L., Bergeron, M., Chow, L. & Tauber, M. G. Tumor necrosis factor α contributes to apoptosis in hippocampal neurons during experimental group B streptococcal meningitis. J. Infect. Dis. 176, 693–697 (1997).
Spranger, M., Schwab, S., Krempien, S., Winterholler, M. & Steiner, T. Excess glutamate levels in the cerebrospinal fluid predict clinical outcome of bacterial meningitis. Arch. Neurol. 53, 992–996 (1996).
Perry, V. L., Young, R. S. K., Aquila, W. J. & During, M. J. Effect of experimental Escherichia coli meningitis on concentrations of excitatory and inhibitory amino acids in the rabbit brain: in vivo microdialysis study. Pediatr. Res. 34, 187–198 (1993).
Leib, S. L., Kim, Y. S., Ferriero, D. M. & Tauber, M. G. Neuroprotective effect of excitatory amino acid antagonist kynurenic acid in experimental bacterial meningitis. J. Infect. Dis. 173, 166–171 (1996). This study shows the role of excitatory amino acids in neuronal injury associated with experimental group B streptococcal meningitis.
Tumani, H. Et al. Inhibition of glutamine synthetase in rabbit pneumococcal meningitis is associated with neuronal apoptosis in the dentate gyrus. Glia 30, 11–18 (2000).
Koedel, U., Gorriz, C., Lorenzl, S. & Pfister, H. -W. Increased endothelin levels in cerebrospinal fluid samples from adults with bacterial meningitis. Clin. Infect. Dis. 25, 329–330 (1997).
Pfister, L. A. Et al. Endothelin inhibition improves cerebral blood flow and is neuroprotective in pneumococcal meningitis. Ann. Neurol. 47, 329–335 (2000).
Hoffman, J. A., Badger, J. L., Zhang, Y., Huang, S. H. & Kim, K. S. Escherichia coli K1 aslA contributes to invasion of brain microvascular endothelial cells in vitro and in vivo. Infect. Immun. 68, 5062–5067 (2000).
Ostergaard, C. Et al. Inhibition of leukocyte entry into the brain by the selectin blocker fucoidin decreases interleukin-1 (IL-1) levels but increases IL-8 levels in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. Infect. Immun. 68, 3153–3157 (2000).
Koedel, U. & Pfister, H. -W. Protective effect of the antioxidant N-acetyl-L-cysteine in pneumococcal meningitis in the rat. Neurosci. Lett. 225, 33–36 (1997).
Kastenbauer, S., Koedel, U., & Pfister, H. -W. Role of peroxynitrite as a mediator of pathophysiological alterations in experimental pneumococcal meningitis. J. Infect. Dis. 180, 1164–1170 (1999).
Lorenzl, S., et al. Protective effect of a 21-aminosteroid during experimental pneumococcal meningitis. J. Infect. Dis 172, 113–118 (1995).
Microbial Pathogenesis Projects
Terje Dokland, Ph.D.Molecular piracy and the mobilization of Staphylococcus aureus pathogenicity islandsStaphylococcus aureus is an opportunistic pathogen that can cause serious local and systemic infections in humans and livestock. The emergence of virulent strains of community-acquired S. Aureus resistant to antibiotics (e.G. MRSA) has become a significant public health problem. Genes encoding virulence factors in these bacteria are frequently carried on mobile genetic elements, such as bacteriophages and pathogenicity islands (SaPIs). My research is focused on the process of mobilization of SaPIs. In particular, we are interested in the process of "molecular piracy", by which SaPIs usurp gene products produced by specific bacteriophages ("helper" phages) in order to ensure their own mobilization, propagation and spread. These processes are studied by a combination of structural methods (cryo-EM, X-ray crystallography), genetics and biochemical approaches.
Michael Gray, Ph.D.The Gray lab uses a combination of genetic, genomic, and biochemical techniques to study how bacteria sense and respond to their environments. We are particularly interested in the molecular biology of the symbiotic and probiotic bacteria that make up the healthy microbiome. Our current research focuses on the bacterial response to reactive chlorine stress. Reactive chlorine compounds, like hypochlorous acid (the active ingredient in household bleach) are powerful antimicrobial oxidants produced by the immune system during inflammation. We are working to identify new regulators, proteins, and pathways that may influence the interactions between bacteria and their human or animal hosts.
Elliot Lefkowitz, Ph.D.My research interests are directed at contributing to the understanding of microbial genomics and evolution by developing and utilizing computational tools and bioinformatics techniques to mine sequence and other data for significant patterns characteristic of function and/or evolution. This work has included the development of new algorithms for the detection of genomic regulatory motifs; tools for the identification of microbial genes; the development and utilization of High Performance and Grid Computing tools for bioinformatics analysis; and the development and use of tools for analyzing patterns of microbial evolution. I have also been involved in the development of databases, web applications, and analysis tools for the sequencing and annotation of several complete bacterial and viral genomes. Research interests have include the annotation and comparative analysis of the complete genomic sequence of several different Mycoplasma bacteria; the annotation and comparative analysis of the complete genomes of several Streptococcus pneumoniae strains; and the development of bioinformatics resources to support biodefense research on microbial pathogens including poxviruses, viral hemorrhagic fevers, and emerging/re-emerging biological threats. The goals of the latter are to provide bioinformatics resources and analyses that can be used to support the development of environmental detectors, diagnostics, animal models, vaccines, and antimicrobial drugs; as well as provide a better understanding of the molecular biology, pathogenesis, and evolution of microbial pathogens.
Currently, as part of the Biomedical Informatics Component of the UAB Center for Clinical Sciences that I direct, my group is heavily involved in collaborative research projects utilizing next-generation sequencing technologies to help answer a wide variety of research questions. This effort includes the analysis of the human microbiome and its role in human health. Even when at the peak of health, our bodies are colonized by vast numbers of microorganisms. But these populations of microorganisms (our microbiome) may vary with, and contribute to human disease. We are developing and utilizing the computational tools needed to understand the role the microbiome plays in human health and disease.
Frances Lund, Ph.D.One of the key research objectives of the Lund laboratory is to identify the key players that suppress or exacerbate pathologic pulmonary inflammation associated with chronic or acute infection. In one project, we are characterizing the role of the TRPM2 cation channel in regulating acute respiratory distress in response to pulmonary or systemic infection with gram-negative bacteria. TRPM2, although reported to induce inflammation in response to oxidative stress, actually protects the lung from damage following infection or exposure to LPS. Current experiments are directed at determining how TRPM2 acts as anti-oxidant and modulates the infected lung microenvironment.
Suzanne Michalek, Ph.D.We are interested in determining how microbial pathogens evade the host's immune system, and in identifying key virulence antigens for use in vaccine development.
Michael Niederweis, Ph.D.One of the most prominent features of M. Tuberculosis is its unusual outer membrane that plays a crucial role in the intrinsic drug resistance and in survival of M. Tuberculosis in vivo. This membrane is functionalized by intriguing proteins which provide essential functions such as nutrient uptake, have new structures and likely function by novel mechanisms. We discovered the first outer membrane channel protein in mycobacteria, obtained the first crystal structure of a mycobacterial outer membrane protein and demonstrated that mycobacteria indeed have two membranes. Our goal is to identify and characterize outer membrane proteins of M. Tuberculosis. One of the proteins, CpnT, enables the secretion of the major exotoxin of M. Tuberculosis, a NAD+ glycohydrolase which triggers necroptosis in infected macrophages. We use state-of-the-art genetic, biochemical and biophysical approaches to achieve our aims.
Jan Novak, Ph.D.Dr. Novak's research interests in Microbial pathogenesis and genetics include biologically active compounds with anti-bacterial, anti-fungal, or anti-protozoal activity, streptococcal virulence factors, antibiotic resistance, protozoal metabolism, and bacterial glycosylation.
Carlos J Orihuela, Ph.D.The Orihuela laboratory examines the host-pathogen interactions that occur during invasive pneumococcal disease. This includes dissecting at a molecular level how Streptococcus pneumoniae virulence determinants interact with the host, how the host cell responds to infection at the cell signaling level, and how these interactions change with advanced age. Currently the Orihuela laboratory is exploring the new observation that S. Pneumoniae invades the heart and causes long-lasting cardiac damage during pneumonia. Specific topics that are being investigated include necroptosis, a pro-inflammatory cell death pathway, involved in pneumolysin-mediated killing of monocytes and cardiomyocytes, how inflamm-aging enhances permissiveness for bacterial infection through upregulation of homeostatic suppressors meant to keep sterile inflammation under control, and the host response to different bacterial phenotypes during its growth within an infected heart.
Jessica Scoffield, Ph.D.The Scoffield laboratory investigates the role of commensal bacteria in polymicrobial pulmonary and oral infections. Our research has led to the discovery of novel mechanisms used by commensal bacteria that interfere with the pathogenesis of Streptococcus mutans, an oral pathogen that contributes to the formation of dental cariers, and Psudomonas aeruginosa, a multidrug resistant pathogen that causes deadly lung infections in cystic fibrosis patients. We are particularly interested in how nitrosative stress modulates competition between commensals and pathogens. Our work has demonstrated that nitrogenous intermediates generated by commensal bacteria can inhibit the growth of pathogens and provide protection against these pathogens in animal models. Using molecular genetics and a systems biology approach (transcriptomics, proteomics, and metabolomics) we aim to identify commensal bacteria mediated antimicrobioal mechanisms that can be harnessed for potential therapeutic purposes.
Andries Steyn, Ph.D.M. Tuberculosis, the etiological agent of TB is one of the most effective human pathogens and is responsible for 2.2 million deaths every year (1 death every 10 seconds). It is estimated that a total of 225 million new cases and 79 million deaths will occur between 1998 and 2030. Tuberculosis (TB) continues to pose a significant threat to mankind that cannot be conquered without an effective vaccine strategy, which remains unavailable to date. The prophylactic vaccine BCG (Bacille Calmette-Guerin), fails to protect against the most common form of disease, adult pulmonary tuberculosis, and its efficacy varies dramatically e.G., from 0% in South India to 80% in the UK. Since the lungs of an infected patient contain more than a billion bacilli, poor treatment compliance can easily lead to multi drug resistant (MDR) strains. The cost for treating a patient infected with MDR-TB (currently designated as Category C Priority pathogens) can approach $250,000 about 10-15 times the cost for treating a drug-sensitive case. One of the greatest risk factors for TB is HIV, which increases the risk of developing tuberculosis 30-fold.
Our long-term goal is to understand the mechanisms of M. Tuberculosis virulence. The first project involves a gene, whiB3, which appears to play a unique role in the bacterium-host interaction. We established that WhiB3 interacts with the 4.2 domain of the principal sigma factor, RpoV in virulent M. Tuberculosis, but not with RpoV of an attenuated strain containing a single point mutation (Arg515-His) in the 4.2 domain. Our studies showed that the M. Tuberculosis whiB3 mutant behaved identical to the wild-type strain with respect to its ability to replicate in mice, but was attenuated in terms of host survival. In addition, the whiB3 mutant strain showed much reduced lung pathology, compared to wild type infected mice. Intriguingly, we showed that a whiB3 mutant of virulent Mycobacterium bovis was completely impaired for growth in guinea pigs. These mutants define a new class of virulence genes in M. Tuberculosis and M. Bovis. M. Tuberculosis contains seven WhiB homologues that show strong similarity to Streptomyces spp. Proteins that are required for sporulation. We hypothesize that WhiB3 controls a subset of genes required for virulence. It is notable that this virulence gene would not have been detected using conventional screens such as signature mutagenesis, which screen primarily for mutants defective in growth and not virulence.
A second project in the laboratory involves the development and application of "in vivo expression technology (IVET)" to rapidly identify M. Tuberculosis genes that are specifically induced during infection in vivo. Since many bacterial virulence determinants share a unique phenotype - induction in the host; the development of such a system for mycobacteria would be of significance. Subsequently, we have successfully developed a genetic system, which uses the animal as a selective medium to identify M. Tuberculosis genes specifically induced during infection. These in vivo induced genes are poorly expressed on laboratory medium, but exhibit elevated levels of expression in host tissues and suggest that they contribute to growth in restricted host tissues and thus enhance pathogenicity.
A third project in the laboratory is studying signal transduction pathways in M. Tuberculosis. In most bacterial two-component systems, the signals or components of the two-component signaling pathways are mostly uncharacterized. We hypothesized that accessory proteins communicate directly, through direct protein-protein communication with the M. Tuberculosis two component histidine kinases to modulate gene expression. Subsequently, we have shown that the sensing module of the M. Tuberculosis histidine kinase KdpD specifically interacts with two membrane proteins, and that the N-terminal sensing module of KdpD and the histidine kinase domain of KdpD form a ternary complex with these membrane proteins. Our results suggest that the membrane proteins function as accessory or ligand-binding proteins that communicate directly with the sensing domain of KdpD to modulate kdp expression.
Charles Turnbough, Ph.D.There are two major research projects in the Turnbough laboratory. The first project is to determine the structure and function of the outermost exosporium layer of Bacillus anthracis spores, an established weapon of bioterrorism that causes the lethal disease anthrax. The exosporium is a bipartite structure consisting of a paracrystalline basal layer and an external hair-like nap. The filaments of the nap are formed by trimers of the collagen-like glycoprotein BclA, while the basal layer contains approximately 20 different proteins. Most basal layer proteins are structural elements that undergo posttranslational modifications necessary for stable exosporium assembly. The mechanisms and functions of several of these modifications are currently being actively studied. These modifications include multi-site phosphorylation of basal l
Comments
Post a Comment